Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Specific Risk Assessment

The legacy of general health and science information has long provided a foundation for understanding broad physiological principles and therapeutic interventions. Within this context, the dissemination of knowledge regarding bone health and the management of osteoporosis has been a central theme, emphasizing the importance of maintaining skeletal integrity through lifestyle measures and pharmacological support. This established framework has traditionally focused on the benefits of treatments such as bisphosphonates, including Fosamax, in reducing fracture risk. As the scientific discourse matured, attention gradually shifted from general efficacy to a more nuanced examination of potential adverse outcomes associated with long-term exposure. This pivot reflects a natural progression in health communication, where initial broad recommendations are refined by emerging safety considerations. The transition from a general health context to a specific occupational exposure concern arises when considering the populations most consistently exposed to such medications. In mass production environments, particularly those involving pharmaceutical manufacturing or healthcare delivery, workers may encounter higher cumulative doses or more frequent handling of these compounds. This occupational dimension introduces a distinct layer of inquiry, moving beyond patient-focused outcomes to examine how sustained workplace exposure might correlate with rare but serious conditions, such as osteonecrosis of the jaw. Thus, the legacy of general health information now serves as a stepping stone toward investigating these specialized risk scenarios.

Understanding Fosamax and Its Mechanism of Action

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its primary mechanism involves inhibiting bone resorption, thereby increasing bone mass and reducing fracture incidence. However, a serious adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves areas of exposed bone that persist for more than eight weeks, often accompanied by pain, swelling, infection, or drainage. Diagnosis is based on clinical examination and imaging, with a focus on ruling out metastatic disease or other causes of jaw lesions. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Scientific Evidence Linking Fosamax to Osteonecrosis of the Jaw

The mechanistic pathways linking Fosamax to ONJ are rooted in its pharmacological action. Bisphosphonates like alendronate inhibit osteoclast-mediated bone resorption, which can suppress normal bone turnover. In the jawbone, which undergoes frequent remodeling due to dental function and infection, this suppression may impair the ability to repair microdamage and maintain tissue integrity. Multiscale characterization of jawbone in animal models treated with bisphosphonates has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Studies in estrogen-deficient rats have examined the effects of bisphosphonate (alendronate) on jawbone properties, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings suggest that bisphosphonate treatment alters the mechanical and structural characteristics of the jawbone, potentially predisposing it to necrosis under stress such as dental procedures. The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experienced relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Risk Communication

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw. It states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also lists known risk factors and notes that the risk may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that the absolute risk in clinical trial populations may be low. The label also advises discontinuation of bisphosphonate treatment for patients requiring invasive dental procedures to reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For affected patients, causation-related considerations involve assessing individual risk factors, duration of Fosamax use, and the temporal relationship between drug exposure and onset of jaw symptoms. The presence of known risk factors such as dental procedures, cancer diagnosis, or concomitant therapies increases the likelihood that Fosamax contributed to ONJ. The recurrence of symptoms upon rechallenge with bisphosphonates further supports a causal link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients should be informed of the potential risk and advised to maintain good oral hygiene and undergo regular dental check-ups while on bisphosphonate therapy.

Conclusion and Implications

In summary, scientific evidence establishes a connection between Fosamax and osteonecrosis of the jaw through pharmacological mechanisms, clinical reports, and animal studies. The risk is influenced by duration of use and presence of other risk factors. Warnings in the prescribing information address this association, though the absolute risk in clinical trials appears low. Patients and healthcare providers should weigh the benefits of Fosamax for osteoporosis and other indications against the potential for ONJ, particularly in those with additional risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate sodium) is a bisphosphonate medication used to treat and prevent osteoporosis by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk. It is approved for postmenopausal women, men with osteoporosis, glucocorticoid-induced osteoporosis, and Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw and how is it diagnosed?

Osteonecrosis of the jaw (ONJ) is a condition with exposed, non-healing bone in the jaw that persists for more than eight weeks, often with pain, swelling, infection, or drainage. Diagnosis is based on clinical exam and imaging, ruling out other causes (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is the scientific evidence linking Fosamax to ONJ?

Evidence includes pharmacological mechanisms (suppression of bone turnover), animal studies showing altered jawbone properties (https://pubmed.ncbi.nlm.nih.gov/40345077/), clinical reports of ONJ in patients taking bisphosphonates, and recurrence upon rechallenge (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while on Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long does it take for ONJ symptoms to appear after starting Fosamax?

The time to onset of symptoms can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.